Participant flow

Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers · Source last updated 2017-04-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. lapatinib ditosylate: Given orally laboratory biomarker analysis: Correlative studies

   id

   FG000

   title

   Treatment (Lapatinib Ditosylate)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         39

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         39

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

1 enrolled patient was a screen failure.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice